Agentix Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGTX research report →
Price Chart
About the company
Agentix Corp. , a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases.
- CEO
- Riazul Huda
- IPO
- 2015
- Employees
- 2
- HQ
- Dana Point, CA, US
Get TickerSpark's AI analysis on AGTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $801.34K
- P/E
- -1.92
- PEG
- -0.34
- P/S
- 0.00
- P/B
- -0.22
- EV/EBITDA
- -2.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 11.74%
- ROIC
- 9.16%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-445,187
- Net Income
- $-485,636+14.4%
- EPS
- $-0.01+14.8%
- OCF Growth
- +13.2%
- FCF Growth
- +13.2%
- 52W High
- $0.06
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.04
- Beta
- 0.78
- RSI (14)
- 43
- Avg Volume
- 12.70K
No earnings-call transcripts are available for AGTX yet.
- Free Float
- 79.1%
- Shares Outstanding
- 40.07M
- Float Shares
- 31.69M
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 29, 20 | Puzzo Thomas E | other | 0 |
| Mar 29, 20 | Grays Peak Ventures LLC | buy | 767,000 |
| Feb 24, 20 | Grays Peak Ventures LLC | other | 1,407,000 |
| Mar 29, 20 | Winterhalter Michael | buy | 150,000 |
| Nov 22, 19 | Winterhalter Michael | sell | 10,015 |
| Nov 4, 19 | Grays Peak Ventures LLC | buy | 9,358 |
| Nov 4, 19 | Stevens Scott B | buy | 9,358 |
| Nov 4, 19 | Winterhalter Michael | sell | 8,433 |
| Oct 9, 19 | Stevens Scott B | buy | 4,712 |
| Oct 24, 19 | Stevens Scott B | other | 4,712 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AGTX coverage
Recent articles, reports, and earnings notes.
No research on AGTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGTX report →